Emerging therapeutic targets for neuromyelitis optica spectrum disorder

• Published in: Expert opinion on therapeutic targets Vol. 24; no. 3; p. 219
• Main Authors: Tradtrantip, Lukmanee, Asavapanumas, Nithi, Verkman, Alan S
• Format: Journal Article
• Language: English
• Published: England 03.03.2020
• Subjects: Animals; Aquaporin 4 - immunology; Autoantibodies - immunology; Complement System Proteins - metabolism; Drug Development; Humans; Immunoglobulin G - immunology; Molecular Targeted Therapy; Neuromyelitis Optica - drug therapy; Neuromyelitis Optica - immunology; Neuromyelitis Optica - physiopathology; aquaporin-4; autoimmunity; complement; neuroinflammation; astrocyte; NMOSD

: Neuromyelitis optica spectrum disorder (NMOSD) is an inflammatory demyelinating disease of the central nervous system affecting primarily the spinal cord and optic nerves. Most NMOSD patients are seropositive for immunoglobulin G autoantibodies against astrocyte water channel aquaporin-4, called A...